Trials / Terminated
TerminatedNCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Ocellaris Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
Conditions
- Cancer
- Neoplasms
- Metastatic Cancer
- Triple Negative Breast Cancer
- Gastric Cancer
- Cervical Cancer
- Ovarian Cancer
- Hepatocellular Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Urothelial Neoplasm
- Non Small Cell Lung Cancer
- Renal Cell Carcinoma
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Neoplasm
- Squamous Cell Carcinoma
- Sarcoma
- Merkel Cell Carcinoma
- Bladder Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OC-001 | Administered IV. |
| DRUG | Drug: OC-001 in Combination with Avelumab | Administered IV. |
Timeline
- Start date
- 2020-09-24
- Primary completion
- 2025-11-07
- Completion
- 2025-11-07
- First posted
- 2020-02-07
- Last updated
- 2026-01-12
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT04260802. Inclusion in this directory is not an endorsement.